Paradigm Financial Partners, LLC Gilead Sciences, Inc. Transaction History

Paradigm Financial Partners, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$63.15 - $72.88 $230,371 - $265,866	3,648 New	3,648 $250,000
Q4 2023 Feb 05, 2024	BUY	$73.27 - $83.09 $39,052 - $44,286	533 Added 2.2%	24,771 $2.01 Million
Q3 2023 Oct 12, 2023	BUY	$73.94 - $80.67 $77,784 - $84,864	1,052 Added 4.54%	24,238 $1.82 Million
Q2 2023 Jul 13, 2023	BUY	$76.01 - $86.7 $115,079 - $131,263	1,514 Added 6.99%	23,186 $1.79 Million
Q1 2023 Apr 11, 2023	BUY	$77.31 - $88.08 $42,597 - $48,532	551 Added 2.61%	21,672 $1.8 Million
Q4 2022 Jan 27, 2023	BUY	$62.32 - $89.47 $179,232 - $257,315	2,876 Added 15.76%	21,121 $0
Q3 2022 Nov 09, 2022	BUY	$59.54 - $68.01 $453,932 - $518,508	7,624 Added 71.78%	18,245 $1.19 Million
Q2 2022 Jul 27, 2022	BUY	$57.72 - $65.01 $237,286 - $267,256	4,111 Added 63.15%	10,621 $666,000
Q4 2021 Feb 10, 2022	BUY	$64.88 - $73.64 $422,368 - $479,396	6,510 New	6,510 $472,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Paradigm Financial Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Paradigm Financial Partners, LLC with notifications on news.